Still waiting on in-vitro proof of concept trial in H1 and then the very important in-vivo trials in H2.
In terms of proof of concept results there seems no doubt that the CLDN 18.2 protein is a good target for gastric cancers (Claudin 18.2 as a novel therapeutic target | Nature Reviews Clinical Oncology) so the question is how effective is this iNKT CAR.
Given the ALA share price re-rate in March last year was in response to in-vivo results from ALA101. A significant result (from CLDN18.2 targeted in vivo trials, in a solid cancer should re-rate again and make ALA a solid 2 product company.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
10.5¢ |
Change
0.005(5.00%) |
Mkt cap ! $124.8M | |||
| Open | High | Low | Value | Volume |
| 10.0¢ | 10.5¢ | 10.0¢ | $21.83K | 212.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 12 | 443503 | 10.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.5¢ | 424264 | 6 |
View Market Depth
| Last trade - 16.10pm 08/08/2025 (20 minute delay) ? |
| ALA (ASX) Chart |